EU drug regulator to review use of Eli Lilly Mounjaro in multi-dose pen
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2024-02-20 08:00 GMT | Update On 2024-03-22 09:44 GMT
Advertisement
Frankfurt: The European Union's healthcare regulator will this week review the use of Eli Lilly's approved Mounjaro drug against diabetes and obesity when prefilled in a multi-dose injection pen, according to a meeting agenda posted on the watchdog's website on Monday.
The U.S. drugmaker won EU approval for the weekly injection late last year and has initially made starter doses available in member states Germany and Poland packaged in vials, so that patients need to draw the medication into syringes before injection.
Lilly's "Kwikpen", a multi-dose injection device that is good for four weekly subcutaneous shots, will be considered as a new route of administration for Mounjaro in a meeting of an expert panel of the European Medicines agency, according to the agenda.
Lilly has previously said European approval of the pen injector could come by the middle of the year.
Britain last week became the first major market where Mounjaro was launched in the four-week Kwikpen.
Original news source: https://www.reuters.com/business/healthcare-pharmaceuticals/eu-drug-regulator-review-lillys-mounjaro-multi-dose-pen-2024-02-19/
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.